Community-derived protocol. No clinical trials have studied this specific combination. For educational reference only.

Metabolic / Fat-Loss Stack

community

Metabolic · 3 compounds

GLP-1 agonist + 5-Amino-1MQ for appetite control combined with cellular fat oxidation. Optional AOD-9604.

Community-derived protocol. No clinical trials exist for this combination. For research and educational purposes only.

Why This Stack

GLP-1 pathway (appetite/insulin control) + NNMT inhibition (cellular fat oxidation and NAD+ support). AOD-9604 optional for additional lipolysis without affecting GH/IGF-1.

Compounds

Semaglutide

Appetite suppression & insulin control

Follow Wegovy titration schedule

5-Amino-1MQ

NNMT inhibition & fat oxidation

50-150 mg oral daily (or 150-250 mcg SC)

AOD-9604

Additional lipolysis (optional)

250-300 mcg daily SC

Protocol

Duration

16+ weeks

Cycling

Follow GLP-1 titration; introduce 5-Amino-1MQ once stable on GLP-1 dose

Notes

GLP-1 is the primary compound; 5-Amino-1MQ adds metabolic support

Reconstitution Quick Reference

Compound	Vial	BAC Water	Concentration
Semaglutide	5 mg	2 mL	2.50 mg/mL
5-Amino-1MQ	10 mg	2 mL	5.00 mg/mL
AOD-9604	5 mg	2 mL	2.50 mg/mL

Stack Calculator

Estimate cost

Citations

[1]Semaglutide for Obesity. NEJM, 384(11). (Reviewed: 2026-04-12)
[2]NNMT Inhibitors in Obesity. Biochem Pharmacol, 147. (Reviewed: 2026-04-12)